Given the unexplained heterogeneity of the results from previously published meta-analyses [25, 26], the specific antibody used to measure ER expression should be taken into consideration in examinations of the impact of ER expression on ovarian cancer patients’ survival. This evidence concerns the gene ESR1 and ovarian carcinoma.